Ikarian Capital, LLC
13F filer · CIK 1778253 · Dallas, TX
Summary
Ikarian Capital, LLC reported $928.17M across 156 positions in its 13F for 2026 Q2, filed Aug 14, 2026. The largest holdings are ABVX (4.7%), KOD (4.4%), ALMS (2.6%). Versus 2026 Q1, leaving options aside, it opened 27 new positions, added to 18, trimmed 29 and sold out of 28.
Reported value$928.17M
Positions156incl. options
Report period2026 Q2
FiledAug 14, 2026
New positions27
Added18
Trimmed29
Sold out28
Top 25 holdings
By reported value, options listed separately · change vs 2026 Q1
Weight 4.7%Value $43.35MPrice $98.50Shares 329K +470.20%Since Jun 30 -25.33%
Weight 4.4%Value $41.29MPrice $89.92Shares 1.06M -16.28%Since Jun 30 +130.80%
Weight 2.6%Value $24.50MPrice $7.29Shares 871K -28.26%Since Jun 30 -74.09%
Weight 2.6%Value $24.39MPrice $285.65Shares 73K +1.76%Since Jun 30 -14.68%
Weight 2.4%Value $22.59MPrice $58.27Shares 389K -9.33%Since Jun 30 +0.24%
Weight 2.4%Value $22.52MPrice $72.62Shares 272K +84.98%Since Jun 30 -12.27%
Weight 1.9%Value $17.80MPrice $31.49Shares 479K +3.74%Since Jun 30 -15.37%
Weight 1.7%Value $15.56MPrice $25.01Shares 505KSince Jun 30 -18.88%
Weight 1.6%Value $14.87MPrice $3.79Shares 2.15M -20.09%Since Jun 30 -45.23%
Weight 1.6%Value $14.55MPrice $8.57Shares 604K +14.43%Since Jun 30 -64.41%
Weight 1.5%Value $14.32MPrice $31.86Shares 370KSince Jun 30 -17.67%
Weight 1.4%Value $13.30MPrice $32.50Shares 310K +55.00%Since Jun 30 -24.26%
Weight 1.4%Value $13.24MPrice $12.73Shares 808KSince Jun 30 -22.33%
Weight 1.2%Value $11.46MPrice $1.85Shares 788K -22.60%Since Jun 30 -87.29%
Weight 1.2%Value $11.36MPrice $3.13Shares 2.43MSince Jun 30 -32.98%
Weight 1.2%Value $11.31MPrice $26.85Shares 379KSince Jun 30 -10.02%
Weight 1.2%Value $11.13MPrice $13.29Shares 748K +81.39%Since Jun 30 -10.69%
Weight 1.2%Value $10.80MPrice $1.08Shares 4.54M -15.77%Since Jun 30 -54.62%
Weight 1.2%Value $10.75MPrice $26.58Shares 407K -20.91%Since Jun 30 +0.72%
Weight 1.2%Value $10.68MPrice $31.91Shares 309K -36.56%Since Jun 30 -7.72%
Weight 1.0%Value $9.50MPrice $14.35Shares 427K -16.59%Since Jun 30 -35.42%
Weight 0.9%Value $8.73MPrice $20.75Shares 336KSince Jun 30 -20.22%
Weight 0.8%Value $7.81MPrice $20.57Shares 425KSince Jun 30 +11.98%
Weight 0.8%Value $7.25MPrice $21.25Shares 257KSince Jun 30 -24.81%
Weight 0.8%Value $7.19MPrice $4.10Shares 1.22M +2.09%Since Jun 30 -30.51%
| Stock | Weight | Value | Since Jun 30 | Shares change | Action |
|---|---|---|---|---|---|
| 4.7% | $43.35M | -25.33% | +470.20% | Add | |
| 4.4% | $41.29M | +130.80% | -16.28% | Trim | |
| 2.6% | $24.50M | -74.09% | -28.26% | Trim | |
| 2.6% | $24.39M | -14.68% | +1.76% | Add | |
| 2.4% | $22.59M | +0.24% | -9.33% | Trim | |
| 2.4% | $22.52M | -12.27% | +84.98% | Add | |
| 1.9% | $17.80M | -15.37% | +3.74% | Add | |
| 1.7% | $15.56M | -18.88% | — | New | |
| 1.6% | $14.87M | -45.23% | -20.09% | Trim | |
| 1.6% | $14.55M | -64.41% | +14.43% | Add | |
| 1.5% | $14.32M | -17.67% | — | New | |
| 1.4% | $13.30M | -24.26% | +55.00% | Add | |
| 1.4% | $13.24M | -22.33% | — | Hold | |
| 1.2% | $11.46M | -87.29% | -22.60% | Trim | |
| 1.2% | $11.36M | -32.98% | — | New | |
| 1.2% | $11.31M | -10.02% | — | Hold | |
| 1.2% | $11.13M | -10.69% | +81.39% | Add | |
| 1.2% | $10.80M | -54.62% | -15.77% | Trim | |
| 1.2% | $10.75M | +0.72% | -20.91% | Trim | |
| 1.2% | $10.68M | -7.72% | -36.56% | Trim | |
| 1.0% | $9.50M | -35.42% | -16.59% | Trim | |
| 0.9% | $8.73M | -20.22% | — | Hold | |
| 0.8% | $7.81M | +11.98% | — | New | |
| 0.8% | $7.25M | -24.81% | — | Hold | |
| 0.8% | $7.19M | -30.51% | +2.09% | Add |
Weight is the share of the reported 13F value, including options at notional value. “Since Jun 30” compares the latest close with the quarter-end price implied by the filing (value ÷ shares).
Largest buys in 2026 Q2
Largest sells in 2026 Q2
Options
Notional value, listed apart from stocks · top 10 of 30
NEWAMSTERDAM PHARMA COMPANYNo ticker matchPUT$13.56MNew
Source: SEC Form 13F, values as reported by the filer. Filings lag up to 45 days after quarter end and cover only certain long positions. Research only, not investment advice.